Cliff ERS - Search Results

1

The promise and harms of screening for plasma cell dyscrasias.

Mohyuddin GR, Chakraborty R, Cliff ERS. Mohyuddin GR, et al. Among authors: cliff ers. Br J Haematol. 2023 Mar;200(6):704-707. doi: 10.1111/bjh.18634. Epub 2023 Jan 10. Br J Haematol. 2023. PMID: 36626939 Review.

2

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Cliff ERS, Mian H, Mohyuddin GR. Cliff ERS, et al. N Engl J Med. 2022 Nov 3;387(18):1721-1722. doi: 10.1056/NEJMc2211969. N Engl J Med. 2022. PMID: 36322860 No abstract available.

3

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.

Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. Van Oekelen O, et al. Among authors: cliff ers. Blood Cancer J. 2022 Nov 15;12(11):155. doi: 10.1038/s41408-022-00750-1. Blood Cancer J. 2022. PMID: 36379917 Free PMC article. Review. No abstract available.

4

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.

Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Cliff ERS, et al. J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716411 No abstract available.

5

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma.

Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Najjar M, et al. Among authors: cliff ers. JAMA Netw Open. 2023 Nov 1;6(11):e2342195. doi: 10.1001/jamanetworkopen.2023.42195. JAMA Netw Open. 2023. PMID: 37948080 Free PMC article.

6

Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.

Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. Alrawabdeh J, et al. Among authors: cliff ers. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad100. doi: 10.1093/jncics/pkad100. JNCI Cancer Spectr. 2023. PMID: 38006333 Free PMC article.

7

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.

Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA. Mohyuddin GR, et al. Among authors: cliff ers. EClinicalMedicine. 2023 Oct 24;65:102272. doi: 10.1016/j.eclinm.2023.102272. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 38046471 Free PMC article.

8

Use of subjective minimizing language at hematology and oncology conferences: A systematic review.

Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. Abusamak AA, et al. Among authors: cliff ers. J Cancer Policy. 2024 Mar;39:100461. doi: 10.1016/j.jcpo.2023.100461. Epub 2023 Dec 5. J Cancer Policy. 2024. PMID: 38061494

9

Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma.

Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty R. Mellgard G, et al. Among authors: cliff ers. Hemasphere. 2024 Mar 20;8(3):e61. doi: 10.1002/hem3.61. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38510991 Free PMC article. No abstract available.

10

Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee.

Cliff ERS, Janakiram M, Kesselheim AS. Cliff ERS, et al. Lancet Haematol. 2023 May;10(5):e314-e317. doi: 10.1016/S2352-3026(23)00056-X. Lancet Haematol. 2023. PMID: 37142342 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page